Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of “Buy” by Brokerages

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have earned an average rating of “Buy” from the four brokerages that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $18.50.

Several brokerages recently weighed in on DCTH. Stephens initiated coverage on shares of Delcath Systems in a report on Tuesday. They issued an “overweight” rating and a $25.00 price target on the stock. StockNews.com upgraded shares of Delcath Systems to a “sell” rating in a research report on Wednesday, March 27th. Finally, HC Wainwright increased their price target on Delcath Systems from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, March 27th.

Delcath Systems Stock Down 5.4 %

DCTH stock opened at $5.40 on Tuesday. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $7.99. The stock has a market capitalization of $150.01 million, a price-to-earnings ratio of -1.82 and a beta of 0.55. The firm’s fifty day simple moving average is $4.83 and its two-hundred day simple moving average is $4.12.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Tuesday, March 26th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.19. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 563.60%. The company had revenue of $0.54 million during the quarter, compared to analyst estimates of $0.48 million. During the same period in the prior year, the firm earned ($0.86) earnings per share. As a group, equities research analysts expect that Delcath Systems will post -1.45 EPS for the current year.

Insider Transactions at Delcath Systems

In related news, Director Gil Aharon acquired 26,882 shares of Delcath Systems stock in a transaction on Tuesday, March 19th. The stock was purchased at an average cost of $3.72 per share, with a total value of $100,001.04. Following the purchase, the director now directly owns 1,069,710 shares in the company, valued at $3,979,321.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 17.94% of the company’s stock.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. Vivo Capital LLC grew its position in shares of Delcath Systems by 57.4% in the third quarter. Vivo Capital LLC now owns 1,855,191 shares of the company’s stock valued at $7,514,000 after purchasing an additional 676,404 shares during the last quarter. AIGH Capital Management LLC purchased a new stake in Delcath Systems during the 4th quarter worth about $4,918,000. Stonepine Capital Management LLC raised its stake in Delcath Systems by 81.2% in the 3rd quarter. Stonepine Capital Management LLC now owns 686,240 shares of the company’s stock valued at $2,779,000 after purchasing an additional 307,453 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after purchasing an additional 161,678 shares in the last quarter. Finally, Worth Venture Partners LLC acquired a new stake in shares of Delcath Systems during the 4th quarter worth about $1,224,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.